Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Bicalutamide
Waymade Healthcare Plc
L02BB03
Bicalutamide
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08030402
Package leaflet: Information for the user BICALUTAMIDE 50 MG TABLETS Bicalutamide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU . • Keep this leaflet. You may need to read it again _. _ • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS I N THIS LEAFLET: 1. What Bicalutamide 50 mg Tablets are and what they are used for 2. What you need to know before you take Bicalutamide 50 mg Tablets 3. How to take Bicalutamide 50 mg Tablets 4. Possible side effects 5. How to store Bicalutamide 50 mg Tablets 6. Contents of the pack and other information 1. WHAT BICALUTAMIDE 50 MG TABLETS ARE AND WHAT THEY ARE USED FOR Bicalutamide 50 mg Tablets contains a medicine called bicalutamide. This belongs to a group of medicines called ‘anti-androgens’. • Bicalutamide 50 mg Tablets are used to treat prostate cancer. • It works by blocking the effects of male hormones such as testosterone. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BICALUTAMIDE 50 MG TABLETS DO NOT TAKE BICALUTAMIDE 50 MG TABLETS: • if you are allergic to bicalutamide or any of the other ingredients of this medicine (listed in section 6). • if you are already taking a medicine called cisapride or certain anti-histamine medicines (terfenadine or astemizole). • if you are a woman. Do not take Bicalutamide 50 mg Tablets if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Bicalutamide 50 mg Tablets. Bicalutamide must not be given to children. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Bicalutamide 50 mg Tablets: • if you have any of the following: any heart or blood vessel condi Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bicalutamide 50 mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg bicalutamide. Each tablet contains 61 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White round, biconvex film-coated tablet embossed ‘B50’ on one side and plain on other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of advanced prostate cancer in combination with LHRH analogue therapy or surgical castration. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adult males including the elderly: one tablet (50mg) once a day. Treatment with bicalutamide should be started at least 3 days before commencing treatment with an LHRH analogue, or at the same time as surgical castration. Children: Bicalutamide is contra-indicated in children. Renal impairment: no dosage adjustment is necessary for patients with renal impairment. Hepatic impairment: no dosage adjustment is necessary for patients with mild hepatic impairment. Increased accumulation may occur in patients with moderate to severe hepatic impairment (see Section 4.4). 4.3 CONTRAINDICATIONS Bicalutamide is contra-indicated in females and children. Bicalutamide must not be given to any patient who has shown a hypersensitivity reaction to its use or to any excipients of this product. Co-administration of terfenadine, astemizole or cisapride with bicalutamide is contra-indicated. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Initiation of treatment should be under the direct supervision of a specialist Bicalutamide is extensively metabolised in the liver. Data suggests that its elimination may be slower in subjects with severe hepatic impairment and this could lead to increased accumulation of bicalutamide. Therefore, bicalutamide should be used with caution in patients with moderate to severe hepatic impairment. Periodic liver function testing should be considered due to the possibility of hepatic changes. The majority of Read the complete document